Lancet:乳腺癌局部或全麻后复发风险研究

2019-10-21 MedSci MedSci原创

研究认为,区域麻醉-镇痛与全麻-镇痛相比,乳腺癌复发风险无显著差异,而持续切口以及乳房疼痛的频率和严重程度差异也不显著

近日研究人员考察了使用椎旁阻滞镇痛和丙泊酚局部麻醉与使用挥发性麻醉剂七氟醚和阿片类镇痛的全身麻醉对持续切口疼痛及乳腺癌复发风险的影响。

研究在阿根廷、奥地利、中国、德国、爱尔兰、新西兰、新加坡和美国开展,85岁以下,准备接受原发性乳腺癌根治术的患者参与研究,随机接受局部麻醉-镇痛(椎旁阻滞和异丙酚)或全麻(七氟醚)和阿片类镇痛。研究的主要终点为局部或转移性乳腺癌复发,次要终点为6、12个月切口疼痛。

1043名患者接受局部麻醉-镇痛,1065名患者接受全麻,随访36个月。局部麻醉-镇痛组102名患者复发(10%),而全麻组111人复发(10%,HR=0.97)。52%的局部麻醉-镇痛组患者6个月时出现切口疼痛,全麻组为52%,12个月时,局部麻醉-镇痛组28%的患者出现切口疼痛,全麻组为27%(OR=1.0)。组间6、12个月神经性胸痛发生率差异不显著。

研究认为,区域麻醉-镇痛与全麻-镇痛相比,乳腺癌复发风险无显著差异,而持续切口以及乳房疼痛的频率和严重程度差异也不显著。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1905541, encodeId=031d19055411c, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Mon Sep 21 15:41:00 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055680, encodeId=4eeb205568064, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Oct 30 13:41:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830298, encodeId=a3ab1830298ba, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 15 04:41:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405940, encodeId=8bf3140594059, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 23 09:41:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476580, encodeId=7c3614e658003, content=<a href='/topic/show?id=6ff229e7126' target=_blank style='color:#2F92EE;'>#全麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29771, encryptionId=6ff229e7126, topicName=全麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Oct 23 09:41:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1905541, encodeId=031d19055411c, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Mon Sep 21 15:41:00 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055680, encodeId=4eeb205568064, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Oct 30 13:41:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830298, encodeId=a3ab1830298ba, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 15 04:41:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405940, encodeId=8bf3140594059, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 23 09:41:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476580, encodeId=7c3614e658003, content=<a href='/topic/show?id=6ff229e7126' target=_blank style='color:#2F92EE;'>#全麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29771, encryptionId=6ff229e7126, topicName=全麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Oct 23 09:41:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1905541, encodeId=031d19055411c, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Mon Sep 21 15:41:00 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055680, encodeId=4eeb205568064, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Oct 30 13:41:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830298, encodeId=a3ab1830298ba, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 15 04:41:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405940, encodeId=8bf3140594059, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 23 09:41:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476580, encodeId=7c3614e658003, content=<a href='/topic/show?id=6ff229e7126' target=_blank style='color:#2F92EE;'>#全麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29771, encryptionId=6ff229e7126, topicName=全麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Oct 23 09:41:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]
    2020-05-15 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1905541, encodeId=031d19055411c, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Mon Sep 21 15:41:00 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055680, encodeId=4eeb205568064, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Oct 30 13:41:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830298, encodeId=a3ab1830298ba, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 15 04:41:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405940, encodeId=8bf3140594059, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 23 09:41:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476580, encodeId=7c3614e658003, content=<a href='/topic/show?id=6ff229e7126' target=_blank style='color:#2F92EE;'>#全麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29771, encryptionId=6ff229e7126, topicName=全麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Oct 23 09:41:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1905541, encodeId=031d19055411c, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Mon Sep 21 15:41:00 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055680, encodeId=4eeb205568064, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Oct 30 13:41:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830298, encodeId=a3ab1830298ba, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 15 04:41:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405940, encodeId=8bf3140594059, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 23 09:41:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476580, encodeId=7c3614e658003, content=<a href='/topic/show?id=6ff229e7126' target=_blank style='color:#2F92EE;'>#全麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29771, encryptionId=6ff229e7126, topicName=全麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Oct 23 09:41:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]

相关资讯

病例:曲妥“方舟”,HER2阳性乳腺癌的“新”希望

HER2阳性乳腺癌是一种侵袭性强、复发率高、预后不良的乳腺癌类型。临床实践中,HER2阳性乳腺癌患者在肿瘤较大,又有保乳意愿时需要考虑新辅助治疗。新辅助治疗能够缩短手术时间,减少术后并发症,甚至部分患者能够增加保乳、保腋窝的机会。本文分享一例HER2阳性乳腺癌患者通过新辅助治疗获益的病例,分享这类患者的诊疗思路。

AZ/Daiichi的乳腺癌曲妥珠抗体偶联药物ADC获得美国优先审查

阿斯利康(AstraZeneca)和第一三共(Daiichi Sankyo)的曲妥珠单抗-deruxtecan治疗乳腺癌喜获美国食品和药物管理局(FDA)的优先审查,使该药物距离在美国获批又近了一步。

“安然新生,全程守护”乳腺癌患者关爱行动在沪启动:推动乳腺癌全程管理理念落实,助力患者整体健康水平提升

2019年10月21日——每年10月是国际乳腺癌关爱月,今天,由辉瑞中国主办的“安然新生,全程守护”乳腺癌患者关爱行动在沪正式启动。乳腺癌领域多位临床专家、来自全国的数十家主流媒体共同出席了本次活动。活动主办方代表——辉瑞生物制药集团中国区肿瘤及罕见病业务总经理李进晖表示:“辉瑞一直致力于携手各方力量共同推动乳腺癌全程管理的建设和普及,我们希望这一项目的启动,能从患者角度出发,发现患者真正的需求,

Lancet Oncol:绝经后HR+/HER2-转移性乳腺癌一线或二线治疗——内分泌为基础治疗较化疗更优

多项重要的随机临床研究已经证实,内分泌联合靶向治疗用于绝经后HR+/HER2-患者一线或二线治疗,可以带来显着的获益。鉴于此,目前所有主要的国际指南均推荐内分泌为基础的序贯方案应该作为优选方案,除非患者合并内脏危象。然而真实世界数据显示,一线化疗仍然非常常见,即使患者没有合并内脏危象。近日发布在《柳叶刀·肿瘤》(Lancet Oncology)的一项大型网络荟萃分析,系统性评估对比了内分泌治疗和化

聚焦精准 引领未来| BRCA检测推动乳腺癌精准治疗

随着精准医疗时代的到来,生物标志物使得肿瘤的诊疗过程更加精准和规范。BRCA1/2基因突变使女性患乳腺癌风险提高约五倍,尤其在具有家族遗传史、年轻和三阴性乳腺癌患者中,BRCA突变比例高于5%。著名好莱坞女星安吉丽娜·朱莉就是因为基因检测发现自己带有BRCA1基因突变,并且家族中有乳腺癌患病史,毅然接受了预防性双侧乳腺切除。作为一种重要的生物标志物,BRCA检测可用于指导临床试验筛选入组、患者用药

Clin Chem:采用4plex双链数字PCR技术对乳腺癌亚型分类

浸润性导管癌(IDCA)是最常见的浸润性乳腺癌。